![]() ![]() The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Global prevalence of ankylosing spondylitis. 2006 1069(1):212-22.ĭean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Annals of the New York academy of Sciences. Epidemiological aspects of rheumatoid arthritis. Kvien TK, Uhlig T, ØdegÅrd S, Heiberg MS. Comparison of the DAS 28‐CRP and DAS 28‐ESR in patients with rheumatoid arthritis. Sengul I, Akcay‐Yalbuzdag S, Ince B, Goksel‐Karatepe A, Kaya T. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Monti S, Todoerti M, Codullo V, Favalli EG, Biggioggero M, Becciolini A, et al. ![]() Kaida-Yip F, Deshpande K, Saran T et al Biosimilars: Review of current applications, obstacles, and their future in medicine. The therapeutic monoclonal antibody market. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. 77.2% patients perceived the overall therapy with Intacept as excellent, very good, good or OK while 22.8% patients rated Intacept therapy as non-satisfactory.Ĭonclusions: The study leads to the conclusion that Intended biosimilar of etanercept (Intacept) was safe and well tolerated in various rheumatic disorders in a real-world scenario.Ĭuly CR, Keating GM. 51.4% patients observed more than 50% improvement in global disease activity with Intacept while 10% patients did not get any response with the treatment. ![]() About 24% of patients dropped due to various reasons like affordability issue (5.7%), inadequate response (8.6%), no response (10%) and side effects (5.7%). 45% patients had LTBI screen positive and were initiated on chemoprophylaxis with Rifampicin and INH 4weeks prior to Intacept. 10% patients reported adverse events like injection site pain (4.29%), fever (2.86%), redness (1.42%) and weight gain (1.42%). The mean duration of follow up was 8☑.7 months. Results: Total 70 patients were enrolled (41males and 29 females) having RA (42), AS (11), SpA (13), JIA (2) AND PsA (2). Basic demographic profile, disease and duration of therapy, any adverse event, patient’s global assessment of disease activity on visual analogue scale (0 to 100), patient’s overall experience with Intended biosimilar etanercept (Intacept). Methods: In single center, retrospective observational study, all patients were enrolled in routine clinical practice who received Intended biosimilar of Etanercept (Intacept) and the following data was collected. (Intacept) in Rheumatoid arthritis (RA), spondyloarthropathy (SpA), ankylosing Spondylitis (AS), juvenile idiopathic arthritis (JIA) and psoriatic arthritis (PsA). The objective of the present study was to assess the safety profile of intended biosimilar of etanercept developed by Intas pharmaceuticals Ltd. Presently, the data available on the safety and effectiveness of biosimilars is very scarce. Department of Rheumatology, HOD, Max Superspeciality Hospital, Saket, New Delhi, Indiaįellow, Max Superspeciality Hospital, Saket, New Delhi, Indiaīiosimilar safety, Intended biosimilar Intacept Abstractīackground: Biosimilars are expected to provide affordable and quality treatment equivalent to the biologics in various rheumatic disorders. ![]()
0 Comments
Leave a Reply. |